Omixon Founder, Attila Bérces Returns as CEO, Aims to Roll-Out New Products

We are happy to announce that Omixon’s founder and chairman Dr. Attila Bérces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialization of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017. In concert between the incoming and outgoing CEOs,...

 

Read more

Do You Know What it Takes to CE Mark an HLA Typing Product?

Abstract presentation by Omixon’s Senior Technical Lead Assay R&D, Dr. Gergely Tölgyesi, from the latest 14th East-West Immunogenetics Conference (Budapest, Hungary). Abstract: European transplantation laboratories require the use of CE-marked HLA typing products for diagnostic purposes. The CE mark (“Conformité Européenne”, French for European conformity) is a symbol that...

 

Read more